AI assistant
4SC AG — Share Issue/Capital Change 2007
May 10, 2007
5_rns_2007-05-10_9fbeea0e-dfc0-471f-a63b-686f6442f192.html
Share Issue/Capital Change
Open in viewerOpens in your device viewer
News Details
Ad-hoc | 10 May 2007 13:16
4SC AG announces subscription and offering price for new shares
4SC AG / Miscellaneous
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
Planegg-Martinsried, Germany, 10 May 2007 - With the approval of the
Supervisory Board and in agreement with the global coordinator and sole
bookrunner, Conrad Hinrich Donner Bank AG, the Management Board of the
Martinsried-based drug discovery and development company 4SC AG (Frankfurt,
Prime Standard: VSC) today has fixed the subscription and offering price
for the current capital increase at 2.80 Euros per share. As part of the
rights offering, as many as 5,730,682 new shares in the company will be
offered. The rights offering for current shareholders was published on 3
May 2007 in the electronic version of the Federal Gazette and in the
Börsen-Zeitung; the term of subscription will end on 16 May 2007.
Any new shares not purchased as part of the rights offering will be offered
to institutional investors in Germany as well as international
institutional investors via private placements by the Conrad Hinrich Donner
Bank at an offering price of 2.80 Euros per new share as part of a public
offering.
Information and Explaination of the Issuer to this News:
About 4SC
4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of
Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now
with a staff of 60, the company develops novel drug candidates for
inflammatory diseases and cancer using a cheminformatics based technology
platform. Traditional high throughput screening of therapeutic agents has
been transferred from the lab to the computer. Thus, the company offers
substantial cost and time advantages as well as increased success rates in
drug development. 4SC AG uses its patented technology platform to create a
sustainable product pipeline for active agents that are developed in early
clinical phases ('proof of concept') and subsequently result in upfront and
milestone payments as well as participation in sales generated by
out-licensed products to the pharmaceutical industry. There are currently
six projects in the pipeline. The first project on the treatment of
rheumatoid arthritis is currently undergoing clinical phase IIa. Four other
product candidates are in preclinical development and another project is in
the research stage. Furthermore, the company has its technology platform in
co-operation projects with biotech and pharma companies and is already
generating initial revenues.
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
Bettina von Klitzing
Manager Investor Relations und Public Relations
4SC AG
phone: +49 (0) 89 70 07 63 - 0
[email protected]
On behalf of 4SC AG:
Regine Petzsch
komm.passion Schumacher´s AG
phone: +49 (0) 89 48 92 72 - 40
[email protected]
DGAP 10.05.2007
Language: English
Issuer: 4SC AG
Am Klopferspitz 19a
82152 Martinsried Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: [email protected]
www: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Indices:
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin-Bremen, Düsseldorf, München, Stuttgart
End of News DGAP News-Service